Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...
Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...
After hours: January 31 at 4:02:36 p.m. EST ...
After hours: 7:54:59 p.m. EST Loading Chart for SANA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback